2022 Fiscal Year Final Research Report
Development of innovative prevention and treatment methods with Adrenomedullin to the necrotizing enterocolitis
| Project/Area Number |
19K17304
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 52050:Embryonic medicine and pediatrics-related
|
|---|
| Research Institution | University of Miyazaki |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2023-03-31
|
| Keywords | 壊死性腸炎 / アドレノメデュリン / 新生児 / 低出生体重児 / ラットモデル |
|---|
| Outline of Final Research Achievements |
Necrotizing enterocolitis (NEC) is an abdominal emergency with a poor prognosis, especially in preterm and low birth weight infants. Adrenomedullin is a peptide with vasodilatory and anti-inflammatory activity discovered in human adrenal pheochromocytoma tissue. We investigated the prophylactic effect of adrenomedullin for NEC in NEC rat model. The neonatal rat NEC model was used to examine the intestinal tract in the normal saline group, the low-dose adrenomedullin group, and the high-dose adrenomedullin group. The results showed that adrenomedullin treatment tended to ameliorate intestinal tissue damage in NEC rats, but there was no significant difference. Survival rates were not significantly different. These results indicate the potential of adrenomedullin as a treatment for NEC, but the preventive effect of adrenomedullin on NEC needs further studies.
|
| Free Research Field |
小児外科
|
| Academic Significance and Societal Importance of the Research Achievements |
壊死性腸炎は新生児、特に低出生体重児に発症する腸管の壊死を伴う腸管不全であり、高率な死亡率(約40%)を有する疾患である。近年、早産児、低出生体重児の出生数が増加しており、それに伴い生存率を高めるだけでなく、intact survival(後遺症なき生存)が目指されている。一方、アドレノメデュリンは血管新生作用や腸管に対する成長因子、抗炎症作用、臓器保護作用を有するペプチドであり、近年、炎症性腸疾患への臨床応用が期待されている。現在、当研究において壊死性腸炎ラットモデルを用いてアドレノメデュリンの予防効果の可能性が示唆された。更なる検討により壊死性腸炎への臨床応用が期待される。
|
